Melanoma - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Melanoma Market Outlook

Thelansis's "Melanoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Melanoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Melanoma Overview

Melanoma is an aggressive malignancy arising from melanocytes - pigment-producing cells residing predominantly in the skin but also in ocular and mucosal sites - representing the most lethal form of skin cancer due to its pronounced metastatic potential. Ultraviolet radiation-induced DNA damage, particularly cyclobutane pyrimidine dimer formation, drives mutagenesis in sporadic melanoma, while germline CDKN2A mutations underlie familial predisposition. Somatic driver mutations - BRAF V600 in approximately 50%, NRAS in 15-20%, and NF1 or KIT alterations in the remaining subtypes - activate MAPK and PI3K survival pathways. Patients present with evolving pigmented lesions characterised by the ABCDE criteria - asymmetry, border irregularity, colour variation, diameter, and evolution - with diagnosis established by excisional biopsy and histopathological assessment, including Breslow thickness, ulceration, and mitotic rate. Sentinel lymph node biopsy guides locoregional staging, while PET-CT and brain MRI are essential for metastatic evaluation. Surgical excision with appropriate margins remains the cornerstone for localised disease. Adjuvant therapy - pembrolizumab, nivolumab, or BRAF-MEK inhibitor combinations in BRAF-mutated disease - reduces recurrence risk in high-risk resected melanoma. Advanced disease management mirrors metastatic cutaneous melanoma - immune checkpoint inhibitors, BRAF-MEK targeted combinations, and lifileucel TIL therapy for refractory disease. Prognosis is stage-dependent; multidisciplinary management, dermoscopic surveillance, sun protection education, and patient-centred care are integral to optimising outcomes.

Key Highlights

• In France, survival-adjusted prevalent Melanoma cases are projected to increase from 1,356,791 in 2025 to 1,454,815 by 2035.
• Rising awareness and improved screening are contributing to earlier melanoma diagnosis.
• Immune checkpoint inhibitors and targeted therapies have significantly improved survival outcomes.
• Unmet need persists in advanced, resistant, and metastatic melanoma cases.

Market Overview

• The France Melanoma market is projected to grow from USD 270 million in 2025 to USD 840 million by 2035.
• Growth is supported by expanding adoption of immunotherapies and precision oncology approaches.
• Emerging cell therapies and next-generation immunotherapies are expected to drive future market expansion.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Regeneron Pharmaceuticals
• Amgen
• Binhui Biopharmaceutical Co., Ltd.
• Hoffmann-La Roche
• Innovent Biologics (Suzhou) Co. Ltd.
• Bristol-Myers Squibb
• AstraZeneca
• Biocad
• Pfizer
• Novartis Pharmaceuticals
• Merck Sharp & Dohme LLC
• Incyte Corporation
• Sandoz
• ModernaTX, Inc.
• Genentech, Inc.
• Alaunos Therapeutics
• BioNTech SE
• Actelion
• BioAtla, Inc.
• Toray Industries, Inc.
• Eucure (Beijing) Biopharma Co., Ltd.
• Bio-Thera Solutions
• Eisai Inc.
• C4 Therapeutics, Inc.
• Seagen Inc.
• TILT Biotherapeutics Ltd.
• ImmVira Pharma Co. Ltd.
• Shandong Boan Biotechnology Co., Ltd.
• Syndax Pharmaceuticals
• AgonOx, Inc.
• MacroGenics
• Ipsen
• Inhibrx Biosciences, Inc.
• Tvardi Therapeutics, Incorporated
• GlaxoSmithKline